Cosmo Bio Co., Ltd. (3386) AI Stock Analysis

• Market Cap: ¥7.52B
• Dividend Yield: 4.57%
• Average Volume (3M): 81.79K
• Price to Earnings (P/E): 22.1
• Beta (1Y): 0.30
• Revenue Growth: 6.49%
• EPS Growth: -32.16%
• Country: JP
• Employees: 174
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 11.30
• Shares Outstanding: 6,048,000
• 10 Day Avg. Volume: 21,560
• 30 Day Avg. Volume: 81,793
• PEG Ratio: 0.70
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 0.69
• P/FCF Ratio: 20.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ¥1,438.00 ▲(20.84% Upside)
• Action: Upgraded Date: 02/18/26
• Date: Action: Upgraded 02/18/26

Overall score is driven mainly by strong financial resilience from an exceptionally low-debt balance sheet and improved 2025 cash generation. Offsetting this, profitability has weakened significantly versus prior years, while technical signals are mixed and valuation is only moderate (supported by yield but not clearly cheap on P/E).

Positive Factors

Very low leverage / strong balance sheet

An extremely low debt load relative to equity gives enduring financial flexibility. It reduces bankruptcy risk, supports spending on R&D or inventory through cycles, and enables opportunistic M&A or capital returns without straining liquidity, strengthening long-term resilience.

Negative Factors

Material margin compression

Substantially lower margins and earnings indicate structural pressure on profitability, whether from pricing, cost inflation, or product mix shifts. If persistent, this erodes return on invested capital, limits reinvestment capacity, and weakens long-term shareholder value creation.

Cosmo Bio Co., Ltd. Business Overview & Revenue Model

Company Description

Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offer...

Read more

Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offer...

How the Company Makes Money

Cosmo Bio Co., Ltd. generates revenue primarily through the sale of life science research products and laboratory supplies. Key revenue streams include the distribution of high-quality reagents, antibodies, and diagnostic kits to various sectors s...

Read more

Cosmo Bio Co., Ltd. generates revenue primarily through the sale of life science research products and laboratory supplies. Key revenue streams include the distribution of high-quality reagents, antibodies, and diagnostic kits to various sectors s...

Cosmo Bio Co., Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.31B	10.77B	10.04B	9.34B	9.55B	9.23B
Gross Profit	3.48B	3.70B	3.33B	3.25B	3.44B	3.66B
EBITDA	508.00M	509.00M	455.00M	801.00M	931.00M	1.26B
Net Income	254.00M	336.00M	262.00M	442.00M	517.00M	737.00M
Balance Sheet
Total Assets	11.79B	12.66B	11.72B	10.87B	10.31B	10.07B
Cash, Cash Equivalents and Short-Term Investments	3.19B	2.95B	2.69B	3.02B	3.04B	3.56B
Total Debt	490.00M	20.00M	22.00M	24.00M	27.00M	28.00M
Total Liabilities	2.11B	2.70B	2.17B	1.84B	1.69B	1.75B
Stockholders Equity	9.08B	9.37B	8.97B	8.45B	8.05B	7.79B
Cash Flow
Free Cash Flow	0.00	366.00M	25.00M	636.00M	180.00M	507.00M
Operating Cash Flow	0.00	595.00M	241.00M	736.00M	284.00M	648.00M
Investing Cash Flow	0.00	43.00M	-217.00M	-758.00M	-291.00M	-145.00M
Financing Cash Flow	0.00	-283.00M	-479.00M	-201.00M	-236.00M	-420.00M

Cosmo Bio Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1190.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Positive. The current price of 1190 is below the 20-day moving average (MA) of 1294.35, below the 50-day MA of 1318.42, and below the 200-day MA of 1238.01, indicating a neutral trend. The MACD of -10.91 indicates Negative momentum. The RSI at 53.60 is Neutral, neither overbought nor oversold. The STOCH value of 69.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3386.

Cosmo Bio Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4556	85 Outperform	¥9.27B	9.53	―	2.53%	3.14%	-2.85%
4570	72 Outperform	¥13.64B	41.40	―	―	12.91%	37.96%
3386	70 Outperform	¥7.52B	22.07	―	4.57%	6.49%	-32.16%
4978	56 Neutral	¥17.31B	120.78	―	―	1.24%	-33.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥11.31B	-8.14	―	―	-42.49%	-2.37%
4892	48 Neutral	¥6.10B	-12.20	―	―	56.17%	-11.63%